Phase II Trial of ERK Inhibition Alone and in Combination With Autophagy Inhibition in Patients with Metastatic Pancreatic Cancer
Summary
The purpose of this study is to evaluate the safety and efficacy of LY3214996 in combination with hydroxychloroquine sulfate (HCQ) in patients with advanced pancreatic cancer.
General Information
NCT#: NCT04386057
Study ID: 19-529
Trial Phase: Phase II
Trial Sponsor: Eli Lilly, Kimberly Perez
Therapies Used in This Trial: Hydroxychloroquine, LY3214996